WO2009026116A3 - Genemap of the human genes associated with longevity - Google Patents

Genemap of the human genes associated with longevity Download PDF

Info

Publication number
WO2009026116A3
WO2009026116A3 PCT/US2008/073238 US2008073238W WO2009026116A3 WO 2009026116 A3 WO2009026116 A3 WO 2009026116A3 US 2008073238 W US2008073238 W US 2008073238W WO 2009026116 A3 WO2009026116 A3 WO 2009026116A3
Authority
WO
WIPO (PCT)
Prior art keywords
longevity
genemap
genes associated
human genes
relates
Prior art date
Application number
PCT/US2008/073238
Other languages
French (fr)
Other versions
WO2009026116A2 (en
Inventor
Abdelmajid Belouchi
John Verner Raelson
Bruno Paquin
Quynh Nguyen-Huu
Sam Kebache
Eerdewegh Paul Van
Jonathan Segal
Randall David Little
Tim Keith
Original Assignee
Genizon Biosciences Inc
Abdelmajid Belouchi
John Verner Raelson
Bruno Paquin
Quynh Nguyen-Huu
Sam Kebache
Eerdewegh Paul Van
Jonathan Segal
Randall David Little
Tim Keith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genizon Biosciences Inc, Abdelmajid Belouchi, John Verner Raelson, Bruno Paquin, Quynh Nguyen-Huu, Sam Kebache, Eerdewegh Paul Van, Jonathan Segal, Randall David Little, Tim Keith filed Critical Genizon Biosciences Inc
Publication of WO2009026116A2 publication Critical patent/WO2009026116A2/en
Publication of WO2009026116A3 publication Critical patent/WO2009026116A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to longevity and aging related disorders and/or their response to a particular drug or drugs.
PCT/US2008/073238 2007-08-16 2008-08-15 Genemap of the human genes associated with longevity WO2009026116A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93552507P 2007-08-16 2007-08-16
US60/935,525 2007-08-16

Publications (2)

Publication Number Publication Date
WO2009026116A2 WO2009026116A2 (en) 2009-02-26
WO2009026116A3 true WO2009026116A3 (en) 2009-07-30

Family

ID=40378924

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/073238 WO2009026116A2 (en) 2007-08-16 2008-08-15 Genemap of the human genes associated with longevity

Country Status (1)

Country Link
WO (1) WO2009026116A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011054644A1 (en) * 2009-10-14 2011-05-12 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. A low density lipoprotein-related protein 1 splice variant as cancer marker
US9045799B2 (en) 2011-03-09 2015-06-02 Arkray, Inc. Probe for detecting polymorphism in CYP3A gene, method of detecting polymorphism, method of evaluating drug efficacy, and reagent kit for detecting polymorphism
US20190106747A1 (en) * 2016-03-21 2019-04-11 Indiana University Research And Technology Corporation Drugs, pharmacogenomics and biomarkers for acive longevity
JP6989138B2 (en) 2016-06-17 2022-01-05 メディジーン イミュノテラピーズ ゲーエムベーハー T cell receptor and its use
CN111500741A (en) * 2019-01-31 2020-08-07 田小利 Branched chain amino acid metabolism related gene SNV, determination reagent and application thereof
CA3141990A1 (en) * 2019-07-05 2021-01-14 The Francis Crick Institute Limited Novel cancer antigens and methods
CA3177341A1 (en) * 2020-05-20 2021-11-25 Chester Bittencort SACRAMENTO Engineered parkin and uses thereof
JP2023526449A (en) * 2020-05-21 2023-06-21 ニスノバイオ ジーティー，エルエルシー Gene therapy delivery of Parkin mutants with increased activity to treat Parkinson's disease
CA3213004A1 (en) * 2021-03-11 2022-09-15 Mnemo Therapeutics Tumor neoantigenic peptides and uses thereof
KR20240006721A (en) * 2021-03-11 2024-01-15 엥스띠뛰 퀴리 Membrane-transforming neoantigen peptide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022781A1 (en) * 2000-12-29 2004-02-05 Spytek Kimberly A. Proteins and nucleic acids encoding same
US20060166204A1 (en) * 2002-09-26 2006-07-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Parkinson's disease susceptibility haptotype as a tool for genetic screening

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022781A1 (en) * 2000-12-29 2004-02-05 Spytek Kimberly A. Proteins and nucleic acids encoding same
US20060166204A1 (en) * 2002-09-26 2006-07-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Parkinson's disease susceptibility haptotype as a tool for genetic screening

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OHKUBO ET AL.: "Apolipoprotein E and Reelin ligands modulate tau phosphorylation through an Apolipoprotein E receptor/disabled-1/glycogen synthase kinase-3 Beta cascade.", FASEB JOUMAL, 18 December 2002 (2002-12-18) *

Also Published As

Publication number Publication date
WO2009026116A2 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
WO2008016356A3 (en) Genemap of the human genes associated with psoriasis
WO2008112177A3 (en) Genemap of the human genes associated with schizophrenia
WO2008118258A3 (en) Genemap of the human genes associated with adhd
WO2007025085A3 (en) Genemap of the human genes associated with crohn's disease
WO2008067195A3 (en) Genemap of the human genes associated with crohn's disease
WO2006138696A3 (en) Genemap of the human genes associated with longevity
WO2009026116A3 (en) Genemap of the human genes associated with longevity
WO2008085601A3 (en) Genemap of the human genes associated with asthma disease
WO2008014400A8 (en) Crohn disease susceptibility gene
WO2009039244A3 (en) Genemap of the human genes associated with crohn's disease
WO2008151803A3 (en) New polymorphisms in abcb1 associated with a lack of clinical response to medicaments
EP2581453A3 (en) Genetic Markers of Mental Illness
EP2639317A3 (en) Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof
WO2008123901A3 (en) Genemap of the human genes associated with endometriosis
EP2570498A3 (en) Genetic markers of mental illness
JO3076B1 (en) Immunotherapy regimes dependent on apoe status
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2008017038A3 (en) Methods for selecting medications
WO2012018613A3 (en) Genetic make-up modifies cancer outcome
WO2009064973A3 (en) Diagnostic kits and methods for scd or sca therapy selection
WO2005072151A3 (en) Apoe genetic markers associated with age of onset of alzheimer's disease
WO2009036100A3 (en) Prediction of qt prolongation based on snp genotype
EP2134863A4 (en) Genetic alterations on chromosome 16 and methods of use thereof for the diagnosis and treatment of type 1 diabetes
WO2012054681A3 (en) Methods for selecting medications for treating patients having attention-deficit hyperactivity disorder
WO2008055196A3 (en) Genemap of the human genes associated with male pattern baldness

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08828027

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08828027

Country of ref document: EP

Kind code of ref document: A2